{
  "SL_001": {
    "drugs": [
      {
        "name": "olaparib",
        "moa": "PARP inhibitor",
        "efficacy_score": 0.465,
        "confidence": 0.545,
        "evidence_tier": "consider",
        "badges": [
          "PathwayAligned"
        ],
        "evidence_strength": 0.0,
        "citations": [],
        "citations_count": 0,
        "clinvar": {
          "classification": "pathogenic",
          "review_status": null,
          "prior": 0.05
        },
        "evidence_manifest": {
          "pubmed_query": "BRCA1 p.C61G ovarian_cancer",
          "citations": [],
          "clinvar": {
            "classification": "pathogenic",
            "review_status": null
          }
        },
        "insights": {
          "functionality": 0.55,
          "chromatin": 0.522,
          "essentiality": 0.35,
          "regulatory": 0.1
        },
        "rationale": [
          {
            "type": "sequence",
            "value": 0.0,
            "percentile": 0.05
          },
          {
            "type": "pathway",
            "percentile": 1.0,
            "breakdown": {
              "ras_mapk": 0.0,
              "tp53": 0.0
            }
          },
          {
            "type": "evidence",
            "strength": 0.0
          }
        ],
        "meets_evidence_gate": false,
        "insufficient_signal": false
      },
      {
        "name": "niraparib",
        "moa": "PARP inhibitor",
        "efficacy_score": 0.465,
        "confidence": 0.545,
        "evidence_tier": "consider",
        "badges": [
          "PathwayAligned"
        ],
        "evidence_strength": 0.0,
        "citations": [],
        "citations_count": 0,
        "clinvar": {
          "classification": "pathogenic",
          "review_status": null,
          "prior": 0.05
        },
        "evidence_manifest": {
          "pubmed_query": "BRCA1 p.C61G ovarian_cancer",
          "citations": [],
          "clinvar": {
            "classification": "pathogenic",
            "review_status": null
          }
        },
        "insights": {
          "functionality": 0.55,
          "chromatin": 0.522,
          "essentiality": 0.35,
          "regulatory": 0.1
        },
        "rationale": [
          {
            "type": "sequence",
            "value": 0.0,
            "percentile": 0.05
          },
          {
            "type": "pathway",
            "percentile": 1.0,
            "breakdown": {
              "ras_mapk": 0.0,
              "tp53": 0.0
            }
          },
          {
            "type": "evidence",
            "strength": 0.0
          }
        ],
        "meets_evidence_gate": false,
        "insufficient_signal": false
      },
      {
        "name": "rucaparib",
        "moa": "PARP inhibitor",
        "efficacy_score": 0.465,
        "confidence": 0.545,
        "evidence_tier": "consider",
        "badges": [
          "PathwayAligned"
        ],
        "evidence_strength": 0.0,
        "citations": [],
        "citations_count": 0,
        "clinvar": {
          "classification": "pathogenic",
          "review_status": null,
          "prior": 0.05
        },
        "evidence_manifest": {
          "pubmed_query": "BRCA1 p.C61G ovarian_cancer",
          "citations": [],
          "clinvar": {
            "classification": "pathogenic",
            "review_status": null
          }
        },
        "insights": {
          "functionality": 0.55,
          "chromatin": 0.522,
          "essentiality": 0.35,
          "regulatory": 0.1
        },
        "rationale": [
          {
            "type": "sequence",
            "value": 0.0,
            "percentile": 0.05
          },
          {
            "type": "pathway",
            "percentile": 1.0,
            "breakdown": {
              "ras_mapk": 0.0,
              "tp53": 0.0
            }
          },
          {
            "type": "evidence",
            "strength": 0.0
          }
        ],
        "meets_evidence_gate": false,
        "insufficient_signal": false
      },
      {
        "name": "carboplatin",
        "moa": "platinum alkylating agent",
        "efficacy_score": 0.465,
        "confidence": 0.545,
        "evidence_tier": "consider",
        "badges": [
          "PathwayAligned"
        ],
        "evidence_strength": 0.0,
        "citations": [],
        "citations_count": 0,
        "clinvar": {
          "classification": "pathogenic",
          "review_status": null,
          "prior": 0.05
        },
        "evidence_manifest": {
          "pubmed_query": "BRCA1 p.C61G ovarian_cancer",
          "citations": [],
          "clinvar": {
            "classification": "pathogenic",
            "review_status": null
          }
        },
        "insights": {
          "functionality": 0.55,
          "chromatin": 0.522,
          "essentiality": 0.35,
          "regulatory": 0.1
        },
        "rationale": [
          {
            "type": "sequence",
            "value": 0.0,
            "percentile": 0.05
          },
          {
            "type": "pathway",
            "percentile": 1.0,
            "breakdown": {
              "ras_mapk": 0.0,
              "tp53": 0.0
            }
          },
          {
            "type": "evidence",
            "strength": 0.0
          }
        ],
        "meets_evidence_gate": false,
        "insufficient_signal": false
      },
      {
        "name": "bevacizumab",
        "moa": "anti-VEGF",
        "efficacy_score": 0.0,
        "confidence": 0.258,
        "evidence_tier": "insufficient",
        "badges": [],
        "evidence_strength": 0.0,
        "citations": [],
        "citations_count": 0,
        "clinvar": {
          "classification": "pathogenic",
          "review_status": null,
          "prior": 0.05
        },
        "evidence_manifest": {
          "pubmed_query": "BRCA1 p.C61G ovarian_cancer",
          "citations": [],
          "clinvar": {
            "classification": "pathogenic",
            "review_status": null
          }
        },
        "insights": {
          "functionality": 0.55,
          "chromatin": 0.522,
          "essentiality": 0.35,
          "regulatory": 0.1
        },
        "rationale": [
          {
            "type": "sequence",
            "value": 0.0,
            "percentile": 0.05
          },
          {
            "type": "pathway",
            "percentile": 0.0,
            "breakdown": {
              "ras_mapk": 0.0,
              "tp53": 0.0
            }
          },
          {
            "type": "evidence",
            "strength": 0.0
          }
        ],
        "meets_evidence_gate": false,
        "insufficient_signal": true
      },
      {
        "name": "pembrolizumab",
        "moa": "anti-PD-1",
        "efficacy_score": 0.0,
        "confidence": 0.258,
        "evidence_tier": "insufficient",
        "badges": [],
        "evidence_strength": 0.0,
        "citations": [],
        "citations_count": 0,
        "clinvar": {
          "classification": "pathogenic",
          "review_status": null,
          "prior": 0.05
        },
        "evidence_manifest": {
          "pubmed_query": "BRCA1 p.C61G ovarian_cancer",
          "citations": [],
          "clinvar": {
            "classification": "pathogenic",
            "review_status": null
          }
        },
        "insights": {
          "functionality": 0.55,
          "chromatin": 0.522,
          "essentiality": 0.35,
          "regulatory": 0.1
        },
        "rationale": [
          {
            "type": "sequence",
            "value": 0.0,
            "percentile": 0.05
          },
          {
            "type": "pathway",
            "percentile": 0.0,
            "breakdown": {
              "ras_mapk": 0.0,
              "tp53": 0.0
            }
          },
          {
            "type": "evidence",
            "strength": 0.0
          }
        ],
        "meets_evidence_gate": false,
        "insufficient_signal": true
      }
    ],
    "run_signature": "96c5a847-37d3-4ccc-987c-f7dbe1141232",
    "scoring_strategy": {
      "approach": "evo2_adaptive",
      "source": "unknown",
      "models_tested": [
        "evo2_7b"
      ],
      "windows_tested": [
        {
          "flank": 4096,
          "exon_delta": 0.0
        },
        {
          "flank": 8192,
          "exon_delta": 0.0
        },
        {
          "flank": 16384,
          "exon_delta": 0.0
        }
      ],
      "ablation_mode": "SPE"
    },
    "evidence_tier": "consider",
    "provenance": {
      "run_id": "96c5a847-37d3-4ccc-987c-f7dbe1141232",
      "profile": "baseline",
      "cache": "miss",
      "flags": {
        "fusion_active": false,
        "evo_use_delta_only": true,
        "evidence_enabled": true,
        "confidence_v2": false
      },
      "sequence_scoring": {
        "mode": "evo2_adaptive",
        "count": 1
      },
      "confidence_breakdown": {
        "top_drug": "olaparib",
        "confidence": 0.545,
        "tier": "consider",
        "badges": [
          "PathwayAligned"
        ],
        "rationale": [
          {
            "type": "sequence",
            "value": 0.0,
            "percentile": 0.05
          },
          {
            "type": "pathway",
            "percentile": 1.0,
            "breakdown": {
              "ras_mapk": 0.0,
              "tp53": 0.0
            }
          },
          {
            "type": "evidence",
            "strength": 0.0
          }
        ],
        "S_contribution": 0.05,
        "P_contribution": 1.0,
        "E_contribution": 0.0,
        "pathway_disruption": {
          "ddr": 0.05
        }
      },
      "lifts": {
        "ablation_mode": "SPE"
      }
    }
  },
  "SL_002": {
    "drugs": [
      {
        "name": "olaparib",
        "moa": "PARP inhibitor",
        "efficacy_score": 0.76,
        "confidence": 0.57,
        "evidence_tier": "consider",
        "badges": [
          "PathwayAligned"
        ],
        "evidence_strength": 0.2,
        "citations": [],
        "citations_count": 0,
        "clinvar": {
          "classification": "vus",
          "review_status": "criteria_provided",
          "prior": 0.0
        },
        "evidence_manifest": {
          "pubmed_query": "BRCA2 p.K3326* ovarian_cancer",
          "citations": [],
          "clinvar": {
            "classification": "vus",
            "review_status": "criteria_provided"
          }
        },
        "insights": {
          "functionality": 0.55,
          "chromatin": 0.406,
          "essentiality": 0.9,
          "regulatory": 0.1
        },
        "rationale": [
          {
            "type": "sequence",
            "value": 1.0,
            "percentile": 1.0
          },
          {
            "type": "pathway",
            "percentile": 1.0,
            "breakdown": {
              "ras_mapk": 0.0,
              "tp53": 0.0
            }
          },
          {
            "type": "evidence",
            "strength": 0.2
          }
        ],
        "meets_evidence_gate": false,
        "insufficient_signal": false
      },
      {
        "name": "niraparib",
        "moa": "PARP inhibitor",
        "efficacy_score": 0.76,
        "confidence": 0.57,
        "evidence_tier": "consider",
        "badges": [
          "PathwayAligned"
        ],
        "evidence_strength": 0.2,
        "citations": [],
        "citations_count": 0,
        "clinvar": {
          "classification": "vus",
          "review_status": "criteria_provided",
          "prior": 0.0
        },
        "evidence_manifest": {
          "pubmed_query": "BRCA2 p.K3326* ovarian_cancer",
          "citations": [],
          "clinvar": {
            "classification": "vus",
            "review_status": "criteria_provided"
          }
        },
        "insights": {
          "functionality": 0.55,
          "chromatin": 0.406,
          "essentiality": 0.9,
          "regulatory": 0.1
        },
        "rationale": [
          {
            "type": "sequence",
            "value": 1.0,
            "percentile": 1.0
          },
          {
            "type": "pathway",
            "percentile": 1.0,
            "breakdown": {
              "ras_mapk": 0.0,
              "tp53": 0.0
            }
          },
          {
            "type": "evidence",
            "strength": 0.2
          }
        ],
        "meets_evidence_gate": false,
        "insufficient_signal": false
      },
      {
        "name": "rucaparib",
        "moa": "PARP inhibitor",
        "efficacy_score": 0.76,
        "confidence": 0.57,
        "evidence_tier": "consider",
        "badges": [
          "PathwayAligned"
        ],
        "evidence_strength": 0.2,
        "citations": [],
        "citations_count": 0,
        "clinvar": {
          "classification": "vus",
          "review_status": "criteria_provided",
          "prior": 0.0
        },
        "evidence_manifest": {
          "pubmed_query": "BRCA2 p.K3326* ovarian_cancer",
          "citations": [],
          "clinvar": {
            "classification": "vus",
            "review_status": "criteria_provided"
          }
        },
        "insights": {
          "functionality": 0.55,
          "chromatin": 0.406,
          "essentiality": 0.9,
          "regulatory": 0.1
        },
        "rationale": [
          {
            "type": "sequence",
            "value": 1.0,
            "percentile": 1.0
          },
          {
            "type": "pathway",
            "percentile": 1.0,
            "breakdown": {
              "ras_mapk": 0.0,
              "tp53": 0.0
            }
          },
          {
            "type": "evidence",
            "strength": 0.2
          }
        ],
        "meets_evidence_gate": false,
        "insufficient_signal": false
      },
      {
        "name": "carboplatin",
        "moa": "platinum alkylating agent",
        "efficacy_score": 0.76,
        "confidence": 0.57,
        "evidence_tier": "consider",
        "badges": [
          "PathwayAligned"
        ],
        "evidence_strength": 0.2,
        "citations": [],
        "citations_count": 0,
        "clinvar": {
          "classification": "vus",
          "review_status": "criteria_provided",
          "prior": 0.0
        },
        "evidence_manifest": {
          "pubmed_query": "BRCA2 p.K3326* ovarian_cancer",
          "citations": [],
          "clinvar": {
            "classification": "vus",
            "review_status": "criteria_provided"
          }
        },
        "insights": {
          "functionality": 0.55,
          "chromatin": 0.406,
          "essentiality": 0.9,
          "regulatory": 0.1
        },
        "rationale": [
          {
            "type": "sequence",
            "value": 1.0,
            "percentile": 1.0
          },
          {
            "type": "pathway",
            "percentile": 1.0,
            "breakdown": {
              "ras_mapk": 0.0,
              "tp53": 0.0
            }
          },
          {
            "type": "evidence",
            "strength": 0.2
          }
        ],
        "meets_evidence_gate": false,
        "insufficient_signal": false
      },
      {
        "name": "bevacizumab",
        "moa": "anti-VEGF",
        "efficacy_score": 0.3,
        "confidence": 0.52,
        "evidence_tier": "consider",
        "badges": [],
        "evidence_strength": 0.0,
        "citations": [],
        "citations_count": 0,
        "clinvar": {
          "classification": "vus",
          "review_status": "criteria_provided",
          "prior": 0.0
        },
        "evidence_manifest": {
          "pubmed_query": "BRCA2 p.K3326* ovarian_cancer",
          "citations": [],
          "clinvar": {
            "classification": "vus",
            "review_status": "criteria_provided"
          }
        },
        "insights": {
          "functionality": 0.55,
          "chromatin": 0.406,
          "essentiality": 0.9,
          "regulatory": 0.1
        },
        "rationale": [
          {
            "type": "sequence",
            "value": 1.0,
            "percentile": 1.0
          },
          {
            "type": "pathway",
            "percentile": 0.0,
            "breakdown": {
              "ras_mapk": 0.0,
              "tp53": 0.0
            }
          },
          {
            "type": "evidence",
            "strength": 0.0
          }
        ],
        "meets_evidence_gate": false,
        "insufficient_signal": false
      },
      {
        "name": "pembrolizumab",
        "moa": "anti-PD-1",
        "efficacy_score": 0.3,
        "confidence": 0.52,
        "evidence_tier": "consider",
        "badges": [],
        "evidence_strength": 0.0,
        "citations": [],
        "citations_count": 0,
        "clinvar": {
          "classification": "vus",
          "review_status": "criteria_provided",
          "prior": 0.0
        },
        "evidence_manifest": {
          "pubmed_query": "BRCA2 p.K3326* ovarian_cancer",
          "citations": [],
          "clinvar": {
            "classification": "vus",
            "review_status": "criteria_provided"
          }
        },
        "insights": {
          "functionality": 0.55,
          "chromatin": 0.406,
          "essentiality": 0.9,
          "regulatory": 0.1
        },
        "rationale": [
          {
            "type": "sequence",
            "value": 1.0,
            "percentile": 1.0
          },
          {
            "type": "pathway",
            "percentile": 0.0,
            "breakdown": {
              "ras_mapk": 0.0,
              "tp53": 0.0
            }
          },
          {
            "type": "evidence",
            "strength": 0.0
          }
        ],
        "meets_evidence_gate": false,
        "insufficient_signal": false
      }
    ],
    "run_signature": "d78eed99-e083-400a-9b73-088daabf2e26",
    "scoring_strategy": {
      "approach": "evo2_adaptive",
      "source": "unknown",
      "models_tested": [
        "evo2_7b"
      ],
      "windows_tested": [
        {
          "flank": 4096,
          "exon_delta": 0.0
        },
        {
          "flank": 8192,
          "exon_delta": 0.0
        },
        {
          "flank": 16384,
          "exon_delta": 0.0
        }
      ],
      "ablation_mode": "SPE"
    },
    "evidence_tier": "consider",
    "provenance": {
      "run_id": "d78eed99-e083-400a-9b73-088daabf2e26",
      "profile": "baseline",
      "cache": "miss",
      "flags": {
        "fusion_active": false,
        "evo_use_delta_only": true,
        "evidence_enabled": true,
        "confidence_v2": false
      },
      "sequence_scoring": {
        "mode": "evo2_adaptive",
        "count": 1
      },
      "confidence_breakdown": {
        "top_drug": "olaparib",
        "confidence": 0.57,
        "tier": "consider",
        "badges": [
          "PathwayAligned"
        ],
        "rationale": [
          {
            "type": "sequence",
            "value": 1.0,
            "percentile": 1.0
          },
          {
            "type": "pathway",
            "percentile": 1.0,
            "breakdown": {
              "ras_mapk": 0.0,
              "tp53": 0.0
            }
          },
          {
            "type": "evidence",
            "strength": 0.2
          }
        ],
        "S_contribution": 1.0,
        "P_contribution": 1.0,
        "E_contribution": 0.2,
        "pathway_disruption": {
          "ddr": 1.0
        }
      },
      "lifts": {
        "ablation_mode": "SPE"
      }
    }
  },
  "SL_003": {
    "drugs": [
      {
        "name": "olaparib",
        "moa": "PARP inhibitor",
        "efficacy_score": 0.75,
        "confidence": 0.66,
        "evidence_tier": "consider",
        "badges": [
          "PathwayAligned"
        ],
        "evidence_strength": 0.0,
        "citations": [],
        "citations_count": 0,
        "clinvar": {
          "classification": "pathogenic",
          "review_status": null,
          "prior": 0.05
        },
        "evidence_manifest": {
          "pubmed_query": "MBD4 p.R346fs ovarian_cancer",
          "citations": [],
          "clinvar": {
            "classification": "pathogenic",
            "review_status": null
          }
        },
        "insights": {
          "functionality": 0.55,
          "chromatin": 0.685,
          "essentiality": 0.9,
          "regulatory": 0.1
        },
        "rationale": [
          {
            "type": "sequence",
            "value": 1.0,
            "percentile": 1.0
          },
          {
            "type": "pathway",
            "percentile": 1.0,
            "breakdown": {
              "ras_mapk": 0.0,
              "tp53": 0.8
            }
          },
          {
            "type": "evidence",
            "strength": 0.0
          }
        ],
        "meets_evidence_gate": false,
        "insufficient_signal": false
      },
      {
        "name": "niraparib",
        "moa": "PARP inhibitor",
        "efficacy_score": 0.75,
        "confidence": 0.66,
        "evidence_tier": "consider",
        "badges": [
          "PathwayAligned"
        ],
        "evidence_strength": 0.0,
        "citations": [],
        "citations_count": 0,
        "clinvar": {
          "classification": "pathogenic",
          "review_status": null,
          "prior": 0.05
        },
        "evidence_manifest": {
          "pubmed_query": "MBD4 p.R346fs ovarian_cancer",
          "citations": [],
          "clinvar": {
            "classification": "pathogenic",
            "review_status": null
          }
        },
        "insights": {
          "functionality": 0.55,
          "chromatin": 0.685,
          "essentiality": 0.9,
          "regulatory": 0.1
        },
        "rationale": [
          {
            "type": "sequence",
            "value": 1.0,
            "percentile": 1.0
          },
          {
            "type": "pathway",
            "percentile": 1.0,
            "breakdown": {
              "ras_mapk": 0.0,
              "tp53": 0.8
            }
          },
          {
            "type": "evidence",
            "strength": 0.0
          }
        ],
        "meets_evidence_gate": false,
        "insufficient_signal": false
      },
      {
        "name": "rucaparib",
        "moa": "PARP inhibitor",
        "efficacy_score": 0.75,
        "confidence": 0.66,
        "evidence_tier": "consider",
        "badges": [
          "PathwayAligned"
        ],
        "evidence_strength": 0.0,
        "citations": [],
        "citations_count": 0,
        "clinvar": {
          "classification": "pathogenic",
          "review_status": null,
          "prior": 0.05
        },
        "evidence_manifest": {
          "pubmed_query": "MBD4 p.R346fs ovarian_cancer",
          "citations": [],
          "clinvar": {
            "classification": "pathogenic",
            "review_status": null
          }
        },
        "insights": {
          "functionality": 0.55,
          "chromatin": 0.685,
          "essentiality": 0.9,
          "regulatory": 0.1
        },
        "rationale": [
          {
            "type": "sequence",
            "value": 1.0,
            "percentile": 1.0
          },
          {
            "type": "pathway",
            "percentile": 1.0,
            "breakdown": {
              "ras_mapk": 0.0,
              "tp53": 0.8
            }
          },
          {
            "type": "evidence",
            "strength": 0.0
          }
        ],
        "meets_evidence_gate": false,
        "insufficient_signal": false
      },
      {
        "name": "carboplatin",
        "moa": "platinum alkylating agent",
        "efficacy_score": 0.75,
        "confidence": 0.66,
        "evidence_tier": "consider",
        "badges": [
          "PathwayAligned"
        ],
        "evidence_strength": 0.0,
        "citations": [],
        "citations_count": 0,
        "clinvar": {
          "classification": "pathogenic",
          "review_status": null,
          "prior": 0.05
        },
        "evidence_manifest": {
          "pubmed_query": "MBD4 p.R346fs ovarian_cancer",
          "citations": [],
          "clinvar": {
            "classification": "pathogenic",
            "review_status": null
          }
        },
        "insights": {
          "functionality": 0.55,
          "chromatin": 0.685,
          "essentiality": 0.9,
          "regulatory": 0.1
        },
        "rationale": [
          {
            "type": "sequence",
            "value": 1.0,
            "percentile": 1.0
          },
          {
            "type": "pathway",
            "percentile": 1.0,
            "breakdown": {
              "ras_mapk": 0.0,
              "tp53": 0.8
            }
          },
          {
            "type": "evidence",
            "strength": 0.0
          }
        ],
        "meets_evidence_gate": false,
        "insufficient_signal": false
      },
      {
        "name": "bevacizumab",
        "moa": "anti-VEGF",
        "efficacy_score": 0.35,
        "confidence": 0.56,
        "evidence_tier": "consider",
        "badges": [],
        "evidence_strength": 0.0,
        "citations": [],
        "citations_count": 0,
        "clinvar": {
          "classification": "pathogenic",
          "review_status": null,
          "prior": 0.05
        },
        "evidence_manifest": {
          "pubmed_query": "MBD4 p.R346fs ovarian_cancer",
          "citations": [],
          "clinvar": {
            "classification": "pathogenic",
            "review_status": null
          }
        },
        "insights": {
          "functionality": 0.55,
          "chromatin": 0.685,
          "essentiality": 0.9,
          "regulatory": 0.1
        },
        "rationale": [
          {
            "type": "sequence",
            "value": 1.0,
            "percentile": 1.0
          },
          {
            "type": "pathway",
            "percentile": 0.0,
            "breakdown": {
              "ras_mapk": 0.0,
              "tp53": 0.8
            }
          },
          {
            "type": "evidence",
            "strength": 0.0
          }
        ],
        "meets_evidence_gate": false,
        "insufficient_signal": false
      },
      {
        "name": "pembrolizumab",
        "moa": "anti-PD-1",
        "efficacy_score": 0.35,
        "confidence": 0.56,
        "evidence_tier": "consider",
        "badges": [],
        "evidence_strength": 0.0,
        "citations": [],
        "citations_count": 0,
        "clinvar": {
          "classification": "pathogenic",
          "review_status": null,
          "prior": 0.05
        },
        "evidence_manifest": {
          "pubmed_query": "MBD4 p.R346fs ovarian_cancer",
          "citations": [],
          "clinvar": {
            "classification": "pathogenic",
            "review_status": null
          }
        },
        "insights": {
          "functionality": 0.55,
          "chromatin": 0.685,
          "essentiality": 0.9,
          "regulatory": 0.1
        },
        "rationale": [
          {
            "type": "sequence",
            "value": 1.0,
            "percentile": 1.0
          },
          {
            "type": "pathway",
            "percentile": 0.0,
            "breakdown": {
              "ras_mapk": 0.0,
              "tp53": 0.8
            }
          },
          {
            "type": "evidence",
            "strength": 0.0
          }
        ],
        "meets_evidence_gate": false,
        "insufficient_signal": false
      }
    ],
    "run_signature": "99073858-9449-418f-8e01-c69d43a51eab",
    "scoring_strategy": {
      "approach": "evo2_adaptive",
      "source": "unknown",
      "models_tested": [
        "evo2_7b"
      ],
      "windows_tested": [
        {
          "flank": 4096,
          "exon_delta": 0.0
        },
        {
          "flank": 8192,
          "exon_delta": 0.0
        },
        {
          "flank": 16384,
          "exon_delta": 0.0
        }
      ],
      "ablation_mode": "SPE"
    },
    "evidence_tier": "consider",
    "provenance": {
      "run_id": "99073858-9449-418f-8e01-c69d43a51eab",
      "profile": "baseline",
      "cache": "miss",
      "flags": {
        "fusion_active": false,
        "evo_use_delta_only": true,
        "evidence_enabled": true,
        "confidence_v2": false
      },
      "sequence_scoring": {
        "mode": "evo2_adaptive",
        "count": 2
      },
      "confidence_breakdown": {
        "top_drug": "olaparib",
        "confidence": 0.66,
        "tier": "consider",
        "badges": [
          "PathwayAligned"
        ],
        "rationale": [
          {
            "type": "sequence",
            "value": 1.0,
            "percentile": 1.0
          },
          {
            "type": "pathway",
            "percentile": 1.0,
            "breakdown": {
              "ras_mapk": 0.0,
              "tp53": 0.8
            }
          },
          {
            "type": "evidence",
            "strength": 0.0
          }
        ],
        "S_contribution": 1.0,
        "P_contribution": 1.0,
        "E_contribution": 0.0,
        "pathway_disruption": {
          "ddr": 1.0,
          "tp53": 0.8
        }
      },
      "lifts": {
        "ablation_mode": "SPE"
      }
    }
  },
  "SL_004": {
    "drugs": [
      {
        "name": "olaparib",
        "moa": "PARP inhibitor",
        "efficacy_score": 0.84,
        "confidence": 0.58,
        "evidence_tier": "consider",
        "badges": [
          "ClinVar-Strong",
          "PathwayAligned"
        ],
        "evidence_strength": 0.0,
        "citations": [],
        "citations_count": 0,
        "clinvar": {
          "classification": "pathogenic",
          "review_status": "expert_panel",
          "prior": 0.2
        },
        "evidence_manifest": {
          "pubmed_query": "TP53 p.R273H ovarian_cancer",
          "citations": [],
          "clinvar": {
            "classification": "pathogenic",
            "review_status": "expert_panel"
          }
        },
        "insights": {
          "functionality": 0.55,
          "chromatin": 0.471,
          "essentiality": 0.35,
          "regulatory": 0.1
        },
        "rationale": [
          {
            "type": "sequence",
            "value": 0.0001,
            "percentile": 0.8
          },
          {
            "type": "pathway",
            "percentile": 1.0,
            "breakdown": {
              "ras_mapk": 0.0,
              "tp53": 0.8
            }
          },
          {
            "type": "evidence",
            "strength": 0.0
          }
        ],
        "meets_evidence_gate": false,
        "insufficient_signal": false
      },
      {
        "name": "niraparib",
        "moa": "PARP inhibitor",
        "efficacy_score": 0.84,
        "confidence": 0.58,
        "evidence_tier": "consider",
        "badges": [
          "ClinVar-Strong",
          "PathwayAligned"
        ],
        "evidence_strength": 0.0,
        "citations": [],
        "citations_count": 0,
        "clinvar": {
          "classification": "pathogenic",
          "review_status": "expert_panel",
          "prior": 0.2
        },
        "evidence_manifest": {
          "pubmed_query": "TP53 p.R273H ovarian_cancer",
          "citations": [],
          "clinvar": {
            "classification": "pathogenic",
            "review_status": "expert_panel"
          }
        },
        "insights": {
          "functionality": 0.55,
          "chromatin": 0.471,
          "essentiality": 0.35,
          "regulatory": 0.1
        },
        "rationale": [
          {
            "type": "sequence",
            "value": 0.0001,
            "percentile": 0.8
          },
          {
            "type": "pathway",
            "percentile": 1.0,
            "breakdown": {
              "ras_mapk": 0.0,
              "tp53": 0.8
            }
          },
          {
            "type": "evidence",
            "strength": 0.0
          }
        ],
        "meets_evidence_gate": false,
        "insufficient_signal": false
      },
      {
        "name": "rucaparib",
        "moa": "PARP inhibitor",
        "efficacy_score": 0.84,
        "confidence": 0.58,
        "evidence_tier": "consider",
        "badges": [
          "ClinVar-Strong",
          "PathwayAligned"
        ],
        "evidence_strength": 0.0,
        "citations": [],
        "citations_count": 0,
        "clinvar": {
          "classification": "pathogenic",
          "review_status": "expert_panel",
          "prior": 0.2
        },
        "evidence_manifest": {
          "pubmed_query": "TP53 p.R273H ovarian_cancer",
          "citations": [],
          "clinvar": {
            "classification": "pathogenic",
            "review_status": "expert_panel"
          }
        },
        "insights": {
          "functionality": 0.55,
          "chromatin": 0.471,
          "essentiality": 0.35,
          "regulatory": 0.1
        },
        "rationale": [
          {
            "type": "sequence",
            "value": 0.0001,
            "percentile": 0.8
          },
          {
            "type": "pathway",
            "percentile": 1.0,
            "breakdown": {
              "ras_mapk": 0.0,
              "tp53": 0.8
            }
          },
          {
            "type": "evidence",
            "strength": 0.0
          }
        ],
        "meets_evidence_gate": false,
        "insufficient_signal": false
      },
      {
        "name": "carboplatin",
        "moa": "platinum alkylating agent",
        "efficacy_score": 0.84,
        "confidence": 0.58,
        "evidence_tier": "consider",
        "badges": [
          "ClinVar-Strong",
          "PathwayAligned"
        ],
        "evidence_strength": 0.0,
        "citations": [],
        "citations_count": 0,
        "clinvar": {
          "classification": "pathogenic",
          "review_status": "expert_panel",
          "prior": 0.2
        },
        "evidence_manifest": {
          "pubmed_query": "TP53 p.R273H ovarian_cancer",
          "citations": [],
          "clinvar": {
            "classification": "pathogenic",
            "review_status": "expert_panel"
          }
        },
        "insights": {
          "functionality": 0.55,
          "chromatin": 0.471,
          "essentiality": 0.35,
          "regulatory": 0.1
        },
        "rationale": [
          {
            "type": "sequence",
            "value": 0.0001,
            "percentile": 0.8
          },
          {
            "type": "pathway",
            "percentile": 1.0,
            "breakdown": {
              "ras_mapk": 0.0,
              "tp53": 0.8
            }
          },
          {
            "type": "evidence",
            "strength": 0.0
          }
        ],
        "meets_evidence_gate": false,
        "insufficient_signal": false
      },
      {
        "name": "bevacizumab",
        "moa": "anti-VEGF",
        "efficacy_score": 0.0,
        "confidence": 0.53,
        "evidence_tier": "insufficient",
        "badges": [
          "ClinVar-Strong"
        ],
        "evidence_strength": 0.0,
        "citations": [],
        "citations_count": 0,
        "clinvar": {
          "classification": "pathogenic",
          "review_status": "expert_panel",
          "prior": 0.2
        },
        "evidence_manifest": {
          "pubmed_query": "TP53 p.R273H ovarian_cancer",
          "citations": [],
          "clinvar": {
            "classification": "pathogenic",
            "review_status": "expert_panel"
          }
        },
        "insights": {
          "functionality": 0.55,
          "chromatin": 0.471,
          "essentiality": 0.35,
          "regulatory": 0.1
        },
        "rationale": [
          {
            "type": "sequence",
            "value": 0.0001,
            "percentile": 0.8
          },
          {
            "type": "pathway",
            "percentile": 0.0,
            "breakdown": {
              "ras_mapk": 0.0,
              "tp53": 0.8
            }
          },
          {
            "type": "evidence",
            "strength": 0.0
          }
        ],
        "meets_evidence_gate": false,
        "insufficient_signal": true
      },
      {
        "name": "pembrolizumab",
        "moa": "anti-PD-1",
        "efficacy_score": 0.0,
        "confidence": 0.53,
        "evidence_tier": "insufficient",
        "badges": [
          "ClinVar-Strong"
        ],
        "evidence_strength": 0.0,
        "citations": [],
        "citations_count": 0,
        "clinvar": {
          "classification": "pathogenic",
          "review_status": "expert_panel",
          "prior": 0.2
        },
        "evidence_manifest": {
          "pubmed_query": "TP53 p.R273H ovarian_cancer",
          "citations": [],
          "clinvar": {
            "classification": "pathogenic",
            "review_status": "expert_panel"
          }
        },
        "insights": {
          "functionality": 0.55,
          "chromatin": 0.471,
          "essentiality": 0.35,
          "regulatory": 0.1
        },
        "rationale": [
          {
            "type": "sequence",
            "value": 0.0001,
            "percentile": 0.8
          },
          {
            "type": "pathway",
            "percentile": 0.0,
            "breakdown": {
              "ras_mapk": 0.0,
              "tp53": 0.8
            }
          },
          {
            "type": "evidence",
            "strength": 0.0
          }
        ],
        "meets_evidence_gate": false,
        "insufficient_signal": true
      }
    ],
    "run_signature": "0812ac09-5aae-47dc-8d00-e487929c9d5f",
    "scoring_strategy": {
      "approach": "evo2_adaptive",
      "source": "unknown",
      "models_tested": [
        "evo2_7b"
      ],
      "windows_tested": [
        {
          "flank": 4096,
          "exon_delta": 0.0
        },
        {
          "flank": 8192,
          "exon_delta": 0.0
        },
        {
          "flank": 16384,
          "exon_delta": 0.0
        }
      ],
      "ablation_mode": "SPE"
    },
    "evidence_tier": "consider",
    "provenance": {
      "run_id": "0812ac09-5aae-47dc-8d00-e487929c9d5f",
      "profile": "baseline",
      "cache": "miss",
      "flags": {
        "fusion_active": false,
        "evo_use_delta_only": true,
        "evidence_enabled": true,
        "confidence_v2": false
      },
      "sequence_scoring": {
        "mode": "evo2_adaptive",
        "count": 1
      },
      "confidence_breakdown": {
        "top_drug": "olaparib",
        "confidence": 0.58,
        "tier": "consider",
        "badges": [
          "ClinVar-Strong",
          "PathwayAligned"
        ],
        "rationale": [
          {
            "type": "sequence",
            "value": 0.0001,
            "percentile": 0.8
          },
          {
            "type": "pathway",
            "percentile": 1.0,
            "breakdown": {
              "ras_mapk": 0.0,
              "tp53": 0.8
            }
          },
          {
            "type": "evidence",
            "strength": 0.0
          }
        ],
        "S_contribution": 0.8,
        "P_contribution": 1.0,
        "E_contribution": 0.0,
        "pathway_disruption": {
          "tp53": 0.8
        }
      },
      "lifts": {
        "ablation_mode": "SPE"
      }
    }
  },
  "SL_005": {
    "drugs": [
      {
        "name": "olaparib",
        "moa": "PARP inhibitor",
        "efficacy_score": 0.81,
        "confidence": 0.66,
        "evidence_tier": "consider",
        "badges": [
          "PathwayAligned"
        ],
        "evidence_strength": 0.2,
        "citations": [],
        "citations_count": 0,
        "clinvar": {
          "classification": "pathogenic",
          "review_status": null,
          "prior": 0.05
        },
        "evidence_manifest": {
          "pubmed_query": "BRCA1 p.Q563* ovarian_cancer",
          "citations": [],
          "clinvar": {
            "classification": "pathogenic",
            "review_status": null
          }
        },
        "insights": {
          "functionality": 0.55,
          "chromatin": 0.545,
          "essentiality": 0.9,
          "regulatory": 0.1
        },
        "rationale": [
          {
            "type": "sequence",
            "value": 1.0,
            "percentile": 1.0
          },
          {
            "type": "pathway",
            "percentile": 1.0,
            "breakdown": {
              "ras_mapk": 0.0,
              "tp53": 0.8
            }
          },
          {
            "type": "evidence",
            "strength": 0.2
          }
        ],
        "meets_evidence_gate": false,
        "insufficient_signal": false
      },
      {
        "name": "niraparib",
        "moa": "PARP inhibitor",
        "efficacy_score": 0.81,
        "confidence": 0.66,
        "evidence_tier": "consider",
        "badges": [
          "PathwayAligned"
        ],
        "evidence_strength": 0.2,
        "citations": [],
        "citations_count": 0,
        "clinvar": {
          "classification": "pathogenic",
          "review_status": null,
          "prior": 0.05
        },
        "evidence_manifest": {
          "pubmed_query": "BRCA1 p.Q563* ovarian_cancer",
          "citations": [],
          "clinvar": {
            "classification": "pathogenic",
            "review_status": null
          }
        },
        "insights": {
          "functionality": 0.55,
          "chromatin": 0.545,
          "essentiality": 0.9,
          "regulatory": 0.1
        },
        "rationale": [
          {
            "type": "sequence",
            "value": 1.0,
            "percentile": 1.0
          },
          {
            "type": "pathway",
            "percentile": 1.0,
            "breakdown": {
              "ras_mapk": 0.0,
              "tp53": 0.8
            }
          },
          {
            "type": "evidence",
            "strength": 0.2
          }
        ],
        "meets_evidence_gate": false,
        "insufficient_signal": false
      },
      {
        "name": "rucaparib",
        "moa": "PARP inhibitor",
        "efficacy_score": 0.81,
        "confidence": 0.66,
        "evidence_tier": "consider",
        "badges": [
          "PathwayAligned"
        ],
        "evidence_strength": 0.2,
        "citations": [],
        "citations_count": 0,
        "clinvar": {
          "classification": "pathogenic",
          "review_status": null,
          "prior": 0.05
        },
        "evidence_manifest": {
          "pubmed_query": "BRCA1 p.Q563* ovarian_cancer",
          "citations": [],
          "clinvar": {
            "classification": "pathogenic",
            "review_status": null
          }
        },
        "insights": {
          "functionality": 0.55,
          "chromatin": 0.545,
          "essentiality": 0.9,
          "regulatory": 0.1
        },
        "rationale": [
          {
            "type": "sequence",
            "value": 1.0,
            "percentile": 1.0
          },
          {
            "type": "pathway",
            "percentile": 1.0,
            "breakdown": {
              "ras_mapk": 0.0,
              "tp53": 0.8
            }
          },
          {
            "type": "evidence",
            "strength": 0.2
          }
        ],
        "meets_evidence_gate": false,
        "insufficient_signal": false
      },
      {
        "name": "carboplatin",
        "moa": "platinum alkylating agent",
        "efficacy_score": 0.81,
        "confidence": 0.66,
        "evidence_tier": "consider",
        "badges": [
          "PathwayAligned"
        ],
        "evidence_strength": 0.2,
        "citations": [],
        "citations_count": 0,
        "clinvar": {
          "classification": "pathogenic",
          "review_status": null,
          "prior": 0.05
        },
        "evidence_manifest": {
          "pubmed_query": "BRCA1 p.Q563* ovarian_cancer",
          "citations": [],
          "clinvar": {
            "classification": "pathogenic",
            "review_status": null
          }
        },
        "insights": {
          "functionality": 0.55,
          "chromatin": 0.545,
          "essentiality": 0.9,
          "regulatory": 0.1
        },
        "rationale": [
          {
            "type": "sequence",
            "value": 1.0,
            "percentile": 1.0
          },
          {
            "type": "pathway",
            "percentile": 1.0,
            "breakdown": {
              "ras_mapk": 0.0,
              "tp53": 0.8
            }
          },
          {
            "type": "evidence",
            "strength": 0.2
          }
        ],
        "meets_evidence_gate": false,
        "insufficient_signal": false
      },
      {
        "name": "bevacizumab",
        "moa": "anti-VEGF",
        "efficacy_score": 0.35,
        "confidence": 0.56,
        "evidence_tier": "consider",
        "badges": [],
        "evidence_strength": 0.0,
        "citations": [],
        "citations_count": 0,
        "clinvar": {
          "classification": "pathogenic",
          "review_status": null,
          "prior": 0.05
        },
        "evidence_manifest": {
          "pubmed_query": "BRCA1 p.Q563* ovarian_cancer",
          "citations": [],
          "clinvar": {
            "classification": "pathogenic",
            "review_status": null
          }
        },
        "insights": {
          "functionality": 0.55,
          "chromatin": 0.545,
          "essentiality": 0.9,
          "regulatory": 0.1
        },
        "rationale": [
          {
            "type": "sequence",
            "value": 1.0,
            "percentile": 1.0
          },
          {
            "type": "pathway",
            "percentile": 0.0,
            "breakdown": {
              "ras_mapk": 0.0,
              "tp53": 0.8
            }
          },
          {
            "type": "evidence",
            "strength": 0.0
          }
        ],
        "meets_evidence_gate": false,
        "insufficient_signal": false
      },
      {
        "name": "pembrolizumab",
        "moa": "anti-PD-1",
        "efficacy_score": 0.35,
        "confidence": 0.56,
        "evidence_tier": "consider",
        "badges": [],
        "evidence_strength": 0.0,
        "citations": [],
        "citations_count": 0,
        "clinvar": {
          "classification": "pathogenic",
          "review_status": null,
          "prior": 0.05
        },
        "evidence_manifest": {
          "pubmed_query": "BRCA1 p.Q563* ovarian_cancer",
          "citations": [],
          "clinvar": {
            "classification": "pathogenic",
            "review_status": null
          }
        },
        "insights": {
          "functionality": 0.55,
          "chromatin": 0.545,
          "essentiality": 0.9,
          "regulatory": 0.1
        },
        "rationale": [
          {
            "type": "sequence",
            "value": 1.0,
            "percentile": 1.0
          },
          {
            "type": "pathway",
            "percentile": 0.0,
            "breakdown": {
              "ras_mapk": 0.0,
              "tp53": 0.8
            }
          },
          {
            "type": "evidence",
            "strength": 0.0
          }
        ],
        "meets_evidence_gate": false,
        "insufficient_signal": false
      }
    ],
    "run_signature": "aca20495-70af-44b1-9817-6f9946a269da",
    "scoring_strategy": {
      "approach": "evo2_adaptive",
      "source": "unknown",
      "models_tested": [
        "evo2_7b"
      ],
      "windows_tested": [
        {
          "flank": 4096,
          "exon_delta": 0.0
        },
        {
          "flank": 8192,
          "exon_delta": 0.0
        },
        {
          "flank": 16384,
          "exon_delta": 0.0
        }
      ],
      "ablation_mode": "SPE"
    },
    "evidence_tier": "consider",
    "provenance": {
      "run_id": "aca20495-70af-44b1-9817-6f9946a269da",
      "profile": "baseline",
      "cache": "miss",
      "flags": {
        "fusion_active": false,
        "evo_use_delta_only": true,
        "evidence_enabled": true,
        "confidence_v2": false
      },
      "sequence_scoring": {
        "mode": "evo2_adaptive",
        "count": 2
      },
      "confidence_breakdown": {
        "top_drug": "olaparib",
        "confidence": 0.66,
        "tier": "consider",
        "badges": [
          "PathwayAligned"
        ],
        "rationale": [
          {
            "type": "sequence",
            "value": 1.0,
            "percentile": 1.0
          },
          {
            "type": "pathway",
            "percentile": 1.0,
            "breakdown": {
              "ras_mapk": 0.0,
              "tp53": 0.8
            }
          },
          {
            "type": "evidence",
            "strength": 0.2
          }
        ],
        "S_contribution": 1.0,
        "P_contribution": 1.0,
        "E_contribution": 0.2,
        "pathway_disruption": {
          "ddr": 1.0,
          "tp53": 0.8
        }
      },
      "lifts": {
        "ablation_mode": "SPE"
      }
    }
  },
  "SL_006": {
    "drugs": [
      {
        "name": "olaparib",
        "moa": "PARP inhibitor",
        "efficacy_score": 0.0,
        "confidence": 0.258,
        "evidence_tier": "insufficient",
        "badges": [],
        "evidence_strength": 0.0,
        "citations": [],
        "citations_count": 0,
        "clinvar": {
          "classification": "pathogenic",
          "review_status": null,
          "prior": 0.05
        },
        "evidence_manifest": {
          "pubmed_query": "OR4F5 p.V123M ovarian_cancer",
          "citations": [],
          "clinvar": {
            "classification": "pathogenic",
            "review_status": null
          }
        },
        "insights": {
          "functionality": 0.55,
          "chromatin": 0.622,
          "essentiality": 0.35,
          "regulatory": 0.1
        },
        "rationale": [
          {
            "type": "sequence",
            "value": 0.0,
            "percentile": 0.05
          },
          {
            "type": "pathway",
            "percentile": 0.0,
            "breakdown": {
              "ras_mapk": 0.0,
              "tp53": 0.0
            }
          },
          {
            "type": "evidence",
            "strength": 0.0
          }
        ],
        "meets_evidence_gate": false,
        "insufficient_signal": true
      },
      {
        "name": "niraparib",
        "moa": "PARP inhibitor",
        "efficacy_score": 0.0,
        "confidence": 0.258,
        "evidence_tier": "insufficient",
        "badges": [],
        "evidence_strength": 0.0,
        "citations": [],
        "citations_count": 0,
        "clinvar": {
          "classification": "pathogenic",
          "review_status": null,
          "prior": 0.05
        },
        "evidence_manifest": {
          "pubmed_query": "OR4F5 p.V123M ovarian_cancer",
          "citations": [],
          "clinvar": {
            "classification": "pathogenic",
            "review_status": null
          }
        },
        "insights": {
          "functionality": 0.55,
          "chromatin": 0.622,
          "essentiality": 0.35,
          "regulatory": 0.1
        },
        "rationale": [
          {
            "type": "sequence",
            "value": 0.0,
            "percentile": 0.05
          },
          {
            "type": "pathway",
            "percentile": 0.0,
            "breakdown": {
              "ras_mapk": 0.0,
              "tp53": 0.0
            }
          },
          {
            "type": "evidence",
            "strength": 0.0
          }
        ],
        "meets_evidence_gate": false,
        "insufficient_signal": true
      },
      {
        "name": "rucaparib",
        "moa": "PARP inhibitor",
        "efficacy_score": 0.0,
        "confidence": 0.258,
        "evidence_tier": "insufficient",
        "badges": [],
        "evidence_strength": 0.0,
        "citations": [],
        "citations_count": 0,
        "clinvar": {
          "classification": "pathogenic",
          "review_status": null,
          "prior": 0.05
        },
        "evidence_manifest": {
          "pubmed_query": "OR4F5 p.V123M ovarian_cancer",
          "citations": [],
          "clinvar": {
            "classification": "pathogenic",
            "review_status": null
          }
        },
        "insights": {
          "functionality": 0.55,
          "chromatin": 0.622,
          "essentiality": 0.35,
          "regulatory": 0.1
        },
        "rationale": [
          {
            "type": "sequence",
            "value": 0.0,
            "percentile": 0.05
          },
          {
            "type": "pathway",
            "percentile": 0.0,
            "breakdown": {
              "ras_mapk": 0.0,
              "tp53": 0.0
            }
          },
          {
            "type": "evidence",
            "strength": 0.0
          }
        ],
        "meets_evidence_gate": false,
        "insufficient_signal": true
      },
      {
        "name": "carboplatin",
        "moa": "platinum alkylating agent",
        "efficacy_score": 0.0,
        "confidence": 0.258,
        "evidence_tier": "insufficient",
        "badges": [],
        "evidence_strength": 0.0,
        "citations": [],
        "citations_count": 0,
        "clinvar": {
          "classification": "pathogenic",
          "review_status": null,
          "prior": 0.05
        },
        "evidence_manifest": {
          "pubmed_query": "OR4F5 p.V123M ovarian_cancer",
          "citations": [],
          "clinvar": {
            "classification": "pathogenic",
            "review_status": null
          }
        },
        "insights": {
          "functionality": 0.55,
          "chromatin": 0.622,
          "essentiality": 0.35,
          "regulatory": 0.1
        },
        "rationale": [
          {
            "type": "sequence",
            "value": 0.0,
            "percentile": 0.05
          },
          {
            "type": "pathway",
            "percentile": 0.0,
            "breakdown": {
              "ras_mapk": 0.0,
              "tp53": 0.0
            }
          },
          {
            "type": "evidence",
            "strength": 0.0
          }
        ],
        "meets_evidence_gate": false,
        "insufficient_signal": true
      },
      {
        "name": "bevacizumab",
        "moa": "anti-VEGF",
        "efficacy_score": 0.0,
        "confidence": 0.258,
        "evidence_tier": "insufficient",
        "badges": [],
        "evidence_strength": 0.0,
        "citations": [],
        "citations_count": 0,
        "clinvar": {
          "classification": "pathogenic",
          "review_status": null,
          "prior": 0.05
        },
        "evidence_manifest": {
          "pubmed_query": "OR4F5 p.V123M ovarian_cancer",
          "citations": [],
          "clinvar": {
            "classification": "pathogenic",
            "review_status": null
          }
        },
        "insights": {
          "functionality": 0.55,
          "chromatin": 0.622,
          "essentiality": 0.35,
          "regulatory": 0.1
        },
        "rationale": [
          {
            "type": "sequence",
            "value": 0.0,
            "percentile": 0.05
          },
          {
            "type": "pathway",
            "percentile": 0.0,
            "breakdown": {
              "ras_mapk": 0.0,
              "tp53": 0.0
            }
          },
          {
            "type": "evidence",
            "strength": 0.0
          }
        ],
        "meets_evidence_gate": false,
        "insufficient_signal": true
      },
      {
        "name": "pembrolizumab",
        "moa": "anti-PD-1",
        "efficacy_score": 0.0,
        "confidence": 0.258,
        "evidence_tier": "insufficient",
        "badges": [],
        "evidence_strength": 0.0,
        "citations": [],
        "citations_count": 0,
        "clinvar": {
          "classification": "pathogenic",
          "review_status": null,
          "prior": 0.05
        },
        "evidence_manifest": {
          "pubmed_query": "OR4F5 p.V123M ovarian_cancer",
          "citations": [],
          "clinvar": {
            "classification": "pathogenic",
            "review_status": null
          }
        },
        "insights": {
          "functionality": 0.55,
          "chromatin": 0.622,
          "essentiality": 0.35,
          "regulatory": 0.1
        },
        "rationale": [
          {
            "type": "sequence",
            "value": 0.0,
            "percentile": 0.05
          },
          {
            "type": "pathway",
            "percentile": 0.0,
            "breakdown": {
              "ras_mapk": 0.0,
              "tp53": 0.0
            }
          },
          {
            "type": "evidence",
            "strength": 0.0
          }
        ],
        "meets_evidence_gate": false,
        "insufficient_signal": true
      }
    ],
    "run_signature": "71ff8553-cf0c-434f-8bad-1564640f294e",
    "scoring_strategy": {
      "approach": "evo2_adaptive",
      "source": "unknown",
      "models_tested": [
        "evo2_7b"
      ],
      "windows_tested": [
        {
          "flank": 4096,
          "exon_delta": 0.0
        },
        {
          "flank": 8192,
          "exon_delta": 0.0
        },
        {
          "flank": 16384,
          "exon_delta": 0.0
        }
      ],
      "ablation_mode": "SPE"
    },
    "evidence_tier": "insufficient",
    "provenance": {
      "run_id": "71ff8553-cf0c-434f-8bad-1564640f294e",
      "profile": "baseline",
      "cache": "miss",
      "flags": {
        "fusion_active": false,
        "evo_use_delta_only": true,
        "evidence_enabled": true,
        "confidence_v2": false
      },
      "sequence_scoring": {
        "mode": "evo2_adaptive",
        "count": 1
      },
      "confidence_breakdown": {
        "top_drug": "olaparib",
        "confidence": 0.258,
        "tier": "insufficient",
        "badges": [],
        "rationale": [
          {
            "type": "sequence",
            "value": 0.0,
            "percentile": 0.05
          },
          {
            "type": "pathway",
            "percentile": 0.0,
            "breakdown": {
              "ras_mapk": 0.0,
              "tp53": 0.0
            }
          },
          {
            "type": "evidence",
            "strength": 0.0
          }
        ],
        "S_contribution": 0.05,
        "P_contribution": 0.0,
        "E_contribution": 0.0,
        "pathway_disruption": {}
      },
      "lifts": {
        "ablation_mode": "SPE"
      }
    }
  },
  "SL_007": {
    "drugs": [
      {
        "name": "olaparib",
        "moa": "PARP inhibitor",
        "efficacy_score": 0.0,
        "confidence": 0.217,
        "evidence_tier": "insufficient",
        "badges": [],
        "evidence_strength": 0.0,
        "citations": [],
        "citations_count": 0,
        "clinvar": {
          "classification": "pathogenic",
          "review_status": null,
          "prior": 0.05
        },
        "evidence_manifest": {
          "pubmed_query": "HLA-A p.A74T ovarian_cancer",
          "citations": [],
          "clinvar": {
            "classification": "pathogenic",
            "review_status": null
          }
        },
        "insights": {
          "functionality": 0.55,
          "chromatin": 0.471,
          "essentiality": 0.35,
          "regulatory": 0.1
        },
        "rationale": [
          {
            "type": "sequence",
            "value": 0.0,
            "percentile": 0.05
          },
          {
            "type": "pathway",
            "percentile": 0.0,
            "breakdown": {
              "ras_mapk": 0.0,
              "tp53": 0.0
            }
          },
          {
            "type": "evidence",
            "strength": 0.0
          }
        ],
        "meets_evidence_gate": false,
        "insufficient_signal": true
      },
      {
        "name": "niraparib",
        "moa": "PARP inhibitor",
        "efficacy_score": 0.0,
        "confidence": 0.217,
        "evidence_tier": "insufficient",
        "badges": [],
        "evidence_strength": 0.0,
        "citations": [],
        "citations_count": 0,
        "clinvar": {
          "classification": "pathogenic",
          "review_status": null,
          "prior": 0.05
        },
        "evidence_manifest": {
          "pubmed_query": "HLA-A p.A74T ovarian_cancer",
          "citations": [],
          "clinvar": {
            "classification": "pathogenic",
            "review_status": null
          }
        },
        "insights": {
          "functionality": 0.55,
          "chromatin": 0.471,
          "essentiality": 0.35,
          "regulatory": 0.1
        },
        "rationale": [
          {
            "type": "sequence",
            "value": 0.0,
            "percentile": 0.05
          },
          {
            "type": "pathway",
            "percentile": 0.0,
            "breakdown": {
              "ras_mapk": 0.0,
              "tp53": 0.0
            }
          },
          {
            "type": "evidence",
            "strength": 0.0
          }
        ],
        "meets_evidence_gate": false,
        "insufficient_signal": true
      },
      {
        "name": "rucaparib",
        "moa": "PARP inhibitor",
        "efficacy_score": 0.0,
        "confidence": 0.217,
        "evidence_tier": "insufficient",
        "badges": [],
        "evidence_strength": 0.0,
        "citations": [],
        "citations_count": 0,
        "clinvar": {
          "classification": "pathogenic",
          "review_status": null,
          "prior": 0.05
        },
        "evidence_manifest": {
          "pubmed_query": "HLA-A p.A74T ovarian_cancer",
          "citations": [],
          "clinvar": {
            "classification": "pathogenic",
            "review_status": null
          }
        },
        "insights": {
          "functionality": 0.55,
          "chromatin": 0.471,
          "essentiality": 0.35,
          "regulatory": 0.1
        },
        "rationale": [
          {
            "type": "sequence",
            "value": 0.0,
            "percentile": 0.05
          },
          {
            "type": "pathway",
            "percentile": 0.0,
            "breakdown": {
              "ras_mapk": 0.0,
              "tp53": 0.0
            }
          },
          {
            "type": "evidence",
            "strength": 0.0
          }
        ],
        "meets_evidence_gate": false,
        "insufficient_signal": true
      },
      {
        "name": "carboplatin",
        "moa": "platinum alkylating agent",
        "efficacy_score": 0.0,
        "confidence": 0.217,
        "evidence_tier": "insufficient",
        "badges": [],
        "evidence_strength": 0.0,
        "citations": [],
        "citations_count": 0,
        "clinvar": {
          "classification": "pathogenic",
          "review_status": null,
          "prior": 0.05
        },
        "evidence_manifest": {
          "pubmed_query": "HLA-A p.A74T ovarian_cancer",
          "citations": [],
          "clinvar": {
            "classification": "pathogenic",
            "review_status": null
          }
        },
        "insights": {
          "functionality": 0.55,
          "chromatin": 0.471,
          "essentiality": 0.35,
          "regulatory": 0.1
        },
        "rationale": [
          {
            "type": "sequence",
            "value": 0.0,
            "percentile": 0.05
          },
          {
            "type": "pathway",
            "percentile": 0.0,
            "breakdown": {
              "ras_mapk": 0.0,
              "tp53": 0.0
            }
          },
          {
            "type": "evidence",
            "strength": 0.0
          }
        ],
        "meets_evidence_gate": false,
        "insufficient_signal": true
      },
      {
        "name": "bevacizumab",
        "moa": "anti-VEGF",
        "efficacy_score": 0.0,
        "confidence": 0.217,
        "evidence_tier": "insufficient",
        "badges": [],
        "evidence_strength": 0.0,
        "citations": [],
        "citations_count": 0,
        "clinvar": {
          "classification": "pathogenic",
          "review_status": null,
          "prior": 0.05
        },
        "evidence_manifest": {
          "pubmed_query": "HLA-A p.A74T ovarian_cancer",
          "citations": [],
          "clinvar": {
            "classification": "pathogenic",
            "review_status": null
          }
        },
        "insights": {
          "functionality": 0.55,
          "chromatin": 0.471,
          "essentiality": 0.35,
          "regulatory": 0.1
        },
        "rationale": [
          {
            "type": "sequence",
            "value": 0.0,
            "percentile": 0.05
          },
          {
            "type": "pathway",
            "percentile": 0.0,
            "breakdown": {
              "ras_mapk": 0.0,
              "tp53": 0.0
            }
          },
          {
            "type": "evidence",
            "strength": 0.0
          }
        ],
        "meets_evidence_gate": false,
        "insufficient_signal": true
      },
      {
        "name": "pembrolizumab",
        "moa": "anti-PD-1",
        "efficacy_score": 0.0,
        "confidence": 0.217,
        "evidence_tier": "insufficient",
        "badges": [],
        "evidence_strength": 0.0,
        "citations": [],
        "citations_count": 0,
        "clinvar": {
          "classification": "pathogenic",
          "review_status": null,
          "prior": 0.05
        },
        "evidence_manifest": {
          "pubmed_query": "HLA-A p.A74T ovarian_cancer",
          "citations": [],
          "clinvar": {
            "classification": "pathogenic",
            "review_status": null
          }
        },
        "insights": {
          "functionality": 0.55,
          "chromatin": 0.471,
          "essentiality": 0.35,
          "regulatory": 0.1
        },
        "rationale": [
          {
            "type": "sequence",
            "value": 0.0,
            "percentile": 0.05
          },
          {
            "type": "pathway",
            "percentile": 0.0,
            "breakdown": {
              "ras_mapk": 0.0,
              "tp53": 0.0
            }
          },
          {
            "type": "evidence",
            "strength": 0.0
          }
        ],
        "meets_evidence_gate": false,
        "insufficient_signal": true
      }
    ],
    "run_signature": "3583e574-ee3b-4463-876b-528dcf69b7a2",
    "scoring_strategy": {
      "approach": "evo2_adaptive",
      "source": "unknown",
      "models_tested": [
        "evo2_7b"
      ],
      "windows_tested": [
        {
          "flank": 4096,
          "exon_delta": 0.0
        },
        {
          "flank": 8192,
          "exon_delta": 0.0
        },
        {
          "flank": 16384,
          "exon_delta": 0.0
        }
      ],
      "ablation_mode": "SPE"
    },
    "evidence_tier": "insufficient",
    "provenance": {
      "run_id": "3583e574-ee3b-4463-876b-528dcf69b7a2",
      "profile": "baseline",
      "cache": "miss",
      "flags": {
        "fusion_active": false,
        "evo_use_delta_only": true,
        "evidence_enabled": true,
        "confidence_v2": false
      },
      "sequence_scoring": {
        "mode": "evo2_adaptive",
        "count": 1
      },
      "confidence_breakdown": {
        "top_drug": "olaparib",
        "confidence": 0.217,
        "tier": "insufficient",
        "badges": [],
        "rationale": [
          {
            "type": "sequence",
            "value": 0.0,
            "percentile": 0.05
          },
          {
            "type": "pathway",
            "percentile": 0.0,
            "breakdown": {
              "ras_mapk": 0.0,
              "tp53": 0.0
            }
          },
          {
            "type": "evidence",
            "strength": 0.0
          }
        ],
        "S_contribution": 0.05,
        "P_contribution": 0.0,
        "E_contribution": 0.0,
        "pathway_disruption": {}
      },
      "lifts": {
        "ablation_mode": "SPE"
      }
    }
  },
  "SL_008": {
    "drugs": [
      {
        "name": "olaparib",
        "moa": "PARP inhibitor",
        "efficacy_score": 0.0,
        "confidence": 0.57,
        "evidence_tier": "insufficient",
        "badges": [],
        "evidence_strength": 0.0,
        "citations": [],
        "citations_count": 0,
        "clinvar": {
          "classification": "pathogenic",
          "review_status": null,
          "prior": 0.05
        },
        "evidence_manifest": {
          "pubmed_query": "KRAS p.G12D ovarian_cancer",
          "citations": [],
          "clinvar": {
            "classification": "pathogenic",
            "review_status": null
          }
        },
        "insights": {
          "functionality": 0.55,
          "chromatin": 0.622,
          "essentiality": 0.35,
          "regulatory": 0.1
        },
        "rationale": [
          {
            "type": "sequence",
            "value": 0.0001,
            "percentile": 0.8
          },
          {
            "type": "pathway",
            "percentile": 0.0,
            "breakdown": {
              "ras_mapk": 0.8,
              "tp53": 0.0
            }
          },
          {
            "type": "evidence",
            "strength": 0.0
          }
        ],
        "meets_evidence_gate": false,
        "insufficient_signal": true
      },
      {
        "name": "niraparib",
        "moa": "PARP inhibitor",
        "efficacy_score": 0.0,
        "confidence": 0.57,
        "evidence_tier": "insufficient",
        "badges": [],
        "evidence_strength": 0.0,
        "citations": [],
        "citations_count": 0,
        "clinvar": {
          "classification": "pathogenic",
          "review_status": null,
          "prior": 0.05
        },
        "evidence_manifest": {
          "pubmed_query": "KRAS p.G12D ovarian_cancer",
          "citations": [],
          "clinvar": {
            "classification": "pathogenic",
            "review_status": null
          }
        },
        "insights": {
          "functionality": 0.55,
          "chromatin": 0.622,
          "essentiality": 0.35,
          "regulatory": 0.1
        },
        "rationale": [
          {
            "type": "sequence",
            "value": 0.0001,
            "percentile": 0.8
          },
          {
            "type": "pathway",
            "percentile": 0.0,
            "breakdown": {
              "ras_mapk": 0.8,
              "tp53": 0.0
            }
          },
          {
            "type": "evidence",
            "strength": 0.0
          }
        ],
        "meets_evidence_gate": false,
        "insufficient_signal": true
      },
      {
        "name": "rucaparib",
        "moa": "PARP inhibitor",
        "efficacy_score": 0.0,
        "confidence": 0.57,
        "evidence_tier": "insufficient",
        "badges": [],
        "evidence_strength": 0.0,
        "citations": [],
        "citations_count": 0,
        "clinvar": {
          "classification": "pathogenic",
          "review_status": null,
          "prior": 0.05
        },
        "evidence_manifest": {
          "pubmed_query": "KRAS p.G12D ovarian_cancer",
          "citations": [],
          "clinvar": {
            "classification": "pathogenic",
            "review_status": null
          }
        },
        "insights": {
          "functionality": 0.55,
          "chromatin": 0.622,
          "essentiality": 0.35,
          "regulatory": 0.1
        },
        "rationale": [
          {
            "type": "sequence",
            "value": 0.0001,
            "percentile": 0.8
          },
          {
            "type": "pathway",
            "percentile": 0.0,
            "breakdown": {
              "ras_mapk": 0.8,
              "tp53": 0.0
            }
          },
          {
            "type": "evidence",
            "strength": 0.0
          }
        ],
        "meets_evidence_gate": false,
        "insufficient_signal": true
      },
      {
        "name": "carboplatin",
        "moa": "platinum alkylating agent",
        "efficacy_score": 0.0,
        "confidence": 0.57,
        "evidence_tier": "insufficient",
        "badges": [],
        "evidence_strength": 0.0,
        "citations": [],
        "citations_count": 0,
        "clinvar": {
          "classification": "pathogenic",
          "review_status": null,
          "prior": 0.05
        },
        "evidence_manifest": {
          "pubmed_query": "KRAS p.G12D ovarian_cancer",
          "citations": [],
          "clinvar": {
            "classification": "pathogenic",
            "review_status": null
          }
        },
        "insights": {
          "functionality": 0.55,
          "chromatin": 0.622,
          "essentiality": 0.35,
          "regulatory": 0.1
        },
        "rationale": [
          {
            "type": "sequence",
            "value": 0.0001,
            "percentile": 0.8
          },
          {
            "type": "pathway",
            "percentile": 0.0,
            "breakdown": {
              "ras_mapk": 0.8,
              "tp53": 0.0
            }
          },
          {
            "type": "evidence",
            "strength": 0.0
          }
        ],
        "meets_evidence_gate": false,
        "insufficient_signal": true
      },
      {
        "name": "bevacizumab",
        "moa": "anti-VEGF",
        "efficacy_score": 0.0,
        "confidence": 0.57,
        "evidence_tier": "insufficient",
        "badges": [],
        "evidence_strength": 0.0,
        "citations": [],
        "citations_count": 0,
        "clinvar": {
          "classification": "pathogenic",
          "review_status": null,
          "prior": 0.05
        },
        "evidence_manifest": {
          "pubmed_query": "KRAS p.G12D ovarian_cancer",
          "citations": [],
          "clinvar": {
            "classification": "pathogenic",
            "review_status": null
          }
        },
        "insights": {
          "functionality": 0.55,
          "chromatin": 0.622,
          "essentiality": 0.35,
          "regulatory": 0.1
        },
        "rationale": [
          {
            "type": "sequence",
            "value": 0.0001,
            "percentile": 0.8
          },
          {
            "type": "pathway",
            "percentile": 0.0,
            "breakdown": {
              "ras_mapk": 0.8,
              "tp53": 0.0
            }
          },
          {
            "type": "evidence",
            "strength": 0.0
          }
        ],
        "meets_evidence_gate": false,
        "insufficient_signal": true
      },
      {
        "name": "pembrolizumab",
        "moa": "anti-PD-1",
        "efficacy_score": 0.0,
        "confidence": 0.57,
        "evidence_tier": "insufficient",
        "badges": [],
        "evidence_strength": 0.0,
        "citations": [],
        "citations_count": 0,
        "clinvar": {
          "classification": "pathogenic",
          "review_status": null,
          "prior": 0.05
        },
        "evidence_manifest": {
          "pubmed_query": "KRAS p.G12D ovarian_cancer",
          "citations": [],
          "clinvar": {
            "classification": "pathogenic",
            "review_status": null
          }
        },
        "insights": {
          "functionality": 0.55,
          "chromatin": 0.622,
          "essentiality": 0.35,
          "regulatory": 0.1
        },
        "rationale": [
          {
            "type": "sequence",
            "value": 0.0001,
            "percentile": 0.8
          },
          {
            "type": "pathway",
            "percentile": 0.0,
            "breakdown": {
              "ras_mapk": 0.8,
              "tp53": 0.0
            }
          },
          {
            "type": "evidence",
            "strength": 0.0
          }
        ],
        "meets_evidence_gate": false,
        "insufficient_signal": true
      }
    ],
    "run_signature": "db26b5c0-30a3-49f3-a8fe-c3cd8534cef3",
    "scoring_strategy": {
      "approach": "evo2_adaptive",
      "source": "unknown",
      "models_tested": [
        "evo2_7b"
      ],
      "windows_tested": [
        {
          "flank": 4096,
          "exon_delta": 0.0
        },
        {
          "flank": 8192,
          "exon_delta": 0.0
        },
        {
          "flank": 16384,
          "exon_delta": 0.0
        }
      ],
      "ablation_mode": "SPE"
    },
    "evidence_tier": "insufficient",
    "provenance": {
      "run_id": "db26b5c0-30a3-49f3-a8fe-c3cd8534cef3",
      "profile": "baseline",
      "cache": "miss",
      "flags": {
        "fusion_active": false,
        "evo_use_delta_only": true,
        "evidence_enabled": true,
        "confidence_v2": false
      },
      "sequence_scoring": {
        "mode": "evo2_adaptive",
        "count": 1
      },
      "confidence_breakdown": {
        "top_drug": "olaparib",
        "confidence": 0.57,
        "tier": "insufficient",
        "badges": [],
        "rationale": [
          {
            "type": "sequence",
            "value": 0.0001,
            "percentile": 0.8
          },
          {
            "type": "pathway",
            "percentile": 0.0,
            "breakdown": {
              "ras_mapk": 0.8,
              "tp53": 0.0
            }
          },
          {
            "type": "evidence",
            "strength": 0.0
          }
        ],
        "S_contribution": 0.8,
        "P_contribution": 0.0,
        "E_contribution": 0.0,
        "pathway_disruption": {
          "ras_mapk": 0.8
        }
      },
      "lifts": {
        "ablation_mode": "SPE"
      }
    }
  },
  "SL_009": {
    "drugs": [
      {
        "name": "BRAF inhibitor",
        "moa": "MAPK blockade",
        "efficacy_score": 0.3,
        "confidence": 0.56,
        "evidence_tier": "consider",
        "badges": [],
        "evidence_strength": 0.0,
        "citations": [],
        "citations_count": 0,
        "clinvar": {
          "classification": "vus",
          "review_status": "criteria_provided",
          "prior": 0.0
        },
        "evidence_manifest": {
          "pubmed_query": "BRCA1 p.E23* breast_cancer",
          "citations": [],
          "clinvar": {
            "classification": "vus",
            "review_status": "criteria_provided"
          }
        },
        "insights": {
          "functionality": 0.55,
          "chromatin": 0.5,
          "essentiality": 0.9,
          "regulatory": 0.1
        },
        "rationale": [
          {
            "type": "sequence",
            "value": 1.0,
            "percentile": 1.0
          },
          {
            "type": "pathway",
            "percentile": 0.0,
            "breakdown": {
              "ras_mapk": 0.0,
              "tp53": 0.0
            }
          },
          {
            "type": "evidence",
            "strength": 0.0
          }
        ],
        "meets_evidence_gate": false,
        "insufficient_signal": false
      },
      {
        "name": "MEK inhibitor",
        "moa": "MAPK downstream blockade",
        "efficacy_score": 0.3,
        "confidence": 0.56,
        "evidence_tier": "consider",
        "badges": [],
        "evidence_strength": 0.0,
        "citations": [],
        "citations_count": 0,
        "clinvar": {
          "classification": "vus",
          "review_status": "criteria_provided",
          "prior": 0.0
        },
        "evidence_manifest": {
          "pubmed_query": "BRCA1 p.E23* breast_cancer",
          "citations": [],
          "clinvar": {
            "classification": "vus",
            "review_status": "criteria_provided"
          }
        },
        "insights": {
          "functionality": 0.55,
          "chromatin": 0.5,
          "essentiality": 0.9,
          "regulatory": 0.1
        },
        "rationale": [
          {
            "type": "sequence",
            "value": 1.0,
            "percentile": 1.0
          },
          {
            "type": "pathway",
            "percentile": 0.0,
            "breakdown": {
              "ras_mapk": 0.0,
              "tp53": 0.0
            }
          },
          {
            "type": "evidence",
            "strength": 0.0
          }
        ],
        "meets_evidence_gate": false,
        "insufficient_signal": false
      },
      {
        "name": "IMiD",
        "moa": "immunomodulatory",
        "efficacy_score": 0.3,
        "confidence": 0.56,
        "evidence_tier": "consider",
        "badges": [],
        "evidence_strength": 0.0,
        "citations": [],
        "citations_count": 0,
        "clinvar": {
          "classification": "vus",
          "review_status": "criteria_provided",
          "prior": 0.0
        },
        "evidence_manifest": {
          "pubmed_query": "BRCA1 p.E23* breast_cancer",
          "citations": [],
          "clinvar": {
            "classification": "vus",
            "review_status": "criteria_provided"
          }
        },
        "insights": {
          "functionality": 0.55,
          "chromatin": 0.5,
          "essentiality": 0.9,
          "regulatory": 0.1
        },
        "rationale": [
          {
            "type": "sequence",
            "value": 1.0,
            "percentile": 1.0
          },
          {
            "type": "pathway",
            "percentile": 0.0,
            "breakdown": {
              "ras_mapk": 0.0,
              "tp53": 0.0
            }
          },
          {
            "type": "evidence",
            "strength": 0.0
          }
        ],
        "meets_evidence_gate": false,
        "insufficient_signal": false
      },
      {
        "name": "Proteasome inhibitor",
        "moa": "proteostasis stress",
        "efficacy_score": 0.3,
        "confidence": 0.56,
        "evidence_tier": "consider",
        "badges": [],
        "evidence_strength": 0.0,
        "citations": [],
        "citations_count": 0,
        "clinvar": {
          "classification": "vus",
          "review_status": "criteria_provided",
          "prior": 0.0
        },
        "evidence_manifest": {
          "pubmed_query": "BRCA1 p.E23* breast_cancer",
          "citations": [],
          "clinvar": {
            "classification": "vus",
            "review_status": "criteria_provided"
          }
        },
        "insights": {
          "functionality": 0.55,
          "chromatin": 0.5,
          "essentiality": 0.9,
          "regulatory": 0.1
        },
        "rationale": [
          {
            "type": "sequence",
            "value": 1.0,
            "percentile": 1.0
          },
          {
            "type": "pathway",
            "percentile": 0.0,
            "breakdown": {
              "ras_mapk": 0.0,
              "tp53": 0.0
            }
          },
          {
            "type": "evidence",
            "strength": 0.0
          }
        ],
        "meets_evidence_gate": false,
        "insufficient_signal": false
      },
      {
        "name": "Anti-CD38",
        "moa": "antibody",
        "efficacy_score": 0.3,
        "confidence": 0.56,
        "evidence_tier": "consider",
        "badges": [],
        "evidence_strength": 0.0,
        "citations": [],
        "citations_count": 0,
        "clinvar": {
          "classification": "vus",
          "review_status": "criteria_provided",
          "prior": 0.0
        },
        "evidence_manifest": {
          "pubmed_query": "BRCA1 p.E23* breast_cancer",
          "citations": [],
          "clinvar": {
            "classification": "vus",
            "review_status": "criteria_provided"
          }
        },
        "insights": {
          "functionality": 0.55,
          "chromatin": 0.5,
          "essentiality": 0.9,
          "regulatory": 0.1
        },
        "rationale": [
          {
            "type": "sequence",
            "value": 1.0,
            "percentile": 1.0
          },
          {
            "type": "pathway",
            "percentile": 0.0,
            "breakdown": {
              "ras_mapk": 0.0,
              "tp53": 0.0
            }
          },
          {
            "type": "evidence",
            "strength": 0.0
          }
        ],
        "meets_evidence_gate": false,
        "insufficient_signal": false
      }
    ],
    "run_signature": "b5d90bf0-d577-4321-944f-40c28001cbac",
    "scoring_strategy": {
      "approach": "evo2_adaptive",
      "source": "unknown",
      "models_tested": [
        "evo2_7b"
      ],
      "windows_tested": [
        {
          "flank": 4096,
          "exon_delta": 0.0
        },
        {
          "flank": 8192,
          "exon_delta": 0.0
        },
        {
          "flank": 16384,
          "exon_delta": 0.0
        }
      ],
      "ablation_mode": "SPE"
    },
    "evidence_tier": "consider",
    "provenance": {
      "run_id": "b5d90bf0-d577-4321-944f-40c28001cbac",
      "profile": "baseline",
      "cache": "miss",
      "flags": {
        "fusion_active": false,
        "evo_use_delta_only": true,
        "evidence_enabled": true,
        "confidence_v2": false
      },
      "sequence_scoring": {
        "mode": "evo2_adaptive",
        "count": 2
      },
      "confidence_breakdown": {
        "top_drug": "BRAF inhibitor",
        "confidence": 0.56,
        "tier": "consider",
        "badges": [],
        "rationale": [
          {
            "type": "sequence",
            "value": 1.0,
            "percentile": 1.0
          },
          {
            "type": "pathway",
            "percentile": 0.0,
            "breakdown": {
              "ras_mapk": 0.0,
              "tp53": 0.0
            }
          },
          {
            "type": "evidence",
            "strength": 0.0
          }
        ],
        "S_contribution": 1.0,
        "P_contribution": 0.0,
        "E_contribution": 0.0,
        "pathway_disruption": {
          "ddr": 1.0,
          "pi3k": 0.05
        }
      },
      "lifts": {
        "ablation_mode": "SPE"
      }
    }
  },
  "SL_010": {
    "drugs": [
      {
        "name": "olaparib",
        "moa": "PARP inhibitor",
        "efficacy_score": 0.465,
        "confidence": 0.505,
        "evidence_tier": "consider",
        "badges": [
          "PathwayAligned"
        ],
        "evidence_strength": 0.0,
        "citations": [],
        "citations_count": 0,
        "clinvar": {
          "classification": "pathogenic",
          "review_status": null,
          "prior": 0.05
        },
        "evidence_manifest": {
          "pubmed_query": "BRCA2 p.N372H ovarian_cancer",
          "citations": [],
          "clinvar": {
            "classification": "pathogenic",
            "review_status": null
          }
        },
        "insights": {
          "functionality": 0.55,
          "chromatin": 0.491,
          "essentiality": 0.35,
          "regulatory": 0.1
        },
        "rationale": [
          {
            "type": "sequence",
            "value": 0.0,
            "percentile": 0.05
          },
          {
            "type": "pathway",
            "percentile": 1.0,
            "breakdown": {
              "ras_mapk": 0.0,
              "tp53": 0.8
            }
          },
          {
            "type": "evidence",
            "strength": 0.0
          }
        ],
        "meets_evidence_gate": false,
        "insufficient_signal": false
      },
      {
        "name": "niraparib",
        "moa": "PARP inhibitor",
        "efficacy_score": 0.465,
        "confidence": 0.505,
        "evidence_tier": "consider",
        "badges": [
          "PathwayAligned"
        ],
        "evidence_strength": 0.0,
        "citations": [],
        "citations_count": 0,
        "clinvar": {
          "classification": "pathogenic",
          "review_status": null,
          "prior": 0.05
        },
        "evidence_manifest": {
          "pubmed_query": "BRCA2 p.N372H ovarian_cancer",
          "citations": [],
          "clinvar": {
            "classification": "pathogenic",
            "review_status": null
          }
        },
        "insights": {
          "functionality": 0.55,
          "chromatin": 0.491,
          "essentiality": 0.35,
          "regulatory": 0.1
        },
        "rationale": [
          {
            "type": "sequence",
            "value": 0.0,
            "percentile": 0.05
          },
          {
            "type": "pathway",
            "percentile": 1.0,
            "breakdown": {
              "ras_mapk": 0.0,
              "tp53": 0.8
            }
          },
          {
            "type": "evidence",
            "strength": 0.0
          }
        ],
        "meets_evidence_gate": false,
        "insufficient_signal": false
      },
      {
        "name": "rucaparib",
        "moa": "PARP inhibitor",
        "efficacy_score": 0.465,
        "confidence": 0.505,
        "evidence_tier": "consider",
        "badges": [
          "PathwayAligned"
        ],
        "evidence_strength": 0.0,
        "citations": [],
        "citations_count": 0,
        "clinvar": {
          "classification": "pathogenic",
          "review_status": null,
          "prior": 0.05
        },
        "evidence_manifest": {
          "pubmed_query": "BRCA2 p.N372H ovarian_cancer",
          "citations": [],
          "clinvar": {
            "classification": "pathogenic",
            "review_status": null
          }
        },
        "insights": {
          "functionality": 0.55,
          "chromatin": 0.491,
          "essentiality": 0.35,
          "regulatory": 0.1
        },
        "rationale": [
          {
            "type": "sequence",
            "value": 0.0,
            "percentile": 0.05
          },
          {
            "type": "pathway",
            "percentile": 1.0,
            "breakdown": {
              "ras_mapk": 0.0,
              "tp53": 0.8
            }
          },
          {
            "type": "evidence",
            "strength": 0.0
          }
        ],
        "meets_evidence_gate": false,
        "insufficient_signal": false
      },
      {
        "name": "carboplatin",
        "moa": "platinum alkylating agent",
        "efficacy_score": 0.465,
        "confidence": 0.505,
        "evidence_tier": "consider",
        "badges": [
          "PathwayAligned"
        ],
        "evidence_strength": 0.0,
        "citations": [],
        "citations_count": 0,
        "clinvar": {
          "classification": "pathogenic",
          "review_status": null,
          "prior": 0.05
        },
        "evidence_manifest": {
          "pubmed_query": "BRCA2 p.N372H ovarian_cancer",
          "citations": [],
          "clinvar": {
            "classification": "pathogenic",
            "review_status": null
          }
        },
        "insights": {
          "functionality": 0.55,
          "chromatin": 0.491,
          "essentiality": 0.35,
          "regulatory": 0.1
        },
        "rationale": [
          {
            "type": "sequence",
            "value": 0.0,
            "percentile": 0.05
          },
          {
            "type": "pathway",
            "percentile": 1.0,
            "breakdown": {
              "ras_mapk": 0.0,
              "tp53": 0.8
            }
          },
          {
            "type": "evidence",
            "strength": 0.0
          }
        ],
        "meets_evidence_gate": false,
        "insufficient_signal": false
      },
      {
        "name": "bevacizumab",
        "moa": "anti-VEGF",
        "efficacy_score": 0.0,
        "confidence": 0.217,
        "evidence_tier": "insufficient",
        "badges": [],
        "evidence_strength": 0.0,
        "citations": [],
        "citations_count": 0,
        "clinvar": {
          "classification": "pathogenic",
          "review_status": null,
          "prior": 0.05
        },
        "evidence_manifest": {
          "pubmed_query": "BRCA2 p.N372H ovarian_cancer",
          "citations": [],
          "clinvar": {
            "classification": "pathogenic",
            "review_status": null
          }
        },
        "insights": {
          "functionality": 0.55,
          "chromatin": 0.491,
          "essentiality": 0.35,
          "regulatory": 0.1
        },
        "rationale": [
          {
            "type": "sequence",
            "value": 0.0,
            "percentile": 0.05
          },
          {
            "type": "pathway",
            "percentile": 0.0,
            "breakdown": {
              "ras_mapk": 0.0,
              "tp53": 0.8
            }
          },
          {
            "type": "evidence",
            "strength": 0.0
          }
        ],
        "meets_evidence_gate": false,
        "insufficient_signal": true
      },
      {
        "name": "pembrolizumab",
        "moa": "anti-PD-1",
        "efficacy_score": 0.0,
        "confidence": 0.217,
        "evidence_tier": "insufficient",
        "badges": [],
        "evidence_strength": 0.0,
        "citations": [],
        "citations_count": 0,
        "clinvar": {
          "classification": "pathogenic",
          "review_status": null,
          "prior": 0.05
        },
        "evidence_manifest": {
          "pubmed_query": "BRCA2 p.N372H ovarian_cancer",
          "citations": [],
          "clinvar": {
            "classification": "pathogenic",
            "review_status": null
          }
        },
        "insights": {
          "functionality": 0.55,
          "chromatin": 0.491,
          "essentiality": 0.35,
          "regulatory": 0.1
        },
        "rationale": [
          {
            "type": "sequence",
            "value": 0.0,
            "percentile": 0.05
          },
          {
            "type": "pathway",
            "percentile": 0.0,
            "breakdown": {
              "ras_mapk": 0.0,
              "tp53": 0.8
            }
          },
          {
            "type": "evidence",
            "strength": 0.0
          }
        ],
        "meets_evidence_gate": false,
        "insufficient_signal": true
      }
    ],
    "run_signature": "bafb6d7e-fe24-4d0b-8503-c33bbf0d034a",
    "scoring_strategy": {
      "approach": "evo2_adaptive",
      "source": "unknown",
      "models_tested": [
        "evo2_7b"
      ],
      "windows_tested": [
        {
          "flank": 4096,
          "exon_delta": 0.0
        },
        {
          "flank": 8192,
          "exon_delta": 0.0
        },
        {
          "flank": 16384,
          "exon_delta": 0.0
        }
      ],
      "ablation_mode": "SPE"
    },
    "evidence_tier": "consider",
    "provenance": {
      "run_id": "bafb6d7e-fe24-4d0b-8503-c33bbf0d034a",
      "profile": "baseline",
      "cache": "miss",
      "flags": {
        "fusion_active": false,
        "evo_use_delta_only": true,
        "evidence_enabled": true,
        "confidence_v2": false
      },
      "sequence_scoring": {
        "mode": "evo2_adaptive",
        "count": 2
      },
      "confidence_breakdown": {
        "top_drug": "olaparib",
        "confidence": 0.505,
        "tier": "consider",
        "badges": [
          "PathwayAligned"
        ],
        "rationale": [
          {
            "type": "sequence",
            "value": 0.0,
            "percentile": 0.05
          },
          {
            "type": "pathway",
            "percentile": 1.0,
            "breakdown": {
              "ras_mapk": 0.0,
              "tp53": 0.8
            }
          },
          {
            "type": "evidence",
            "strength": 0.0
          }
        ],
        "S_contribution": 0.05,
        "P_contribution": 1.0,
        "E_contribution": 0.0,
        "pathway_disruption": {
          "ddr": 0.05,
          "tp53": 0.8
        }
      },
      "lifts": {
        "ablation_mode": "SPE"
      }
    }
  }
}